Clinical Trials · NCT07523711
Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity
- Phase
- Phase 1
- Recruitment status
- Recruiting
- Sponsor
- Amgen
- Enrollment
- 45
- Start date
- Apr 2026
- Locations
- 3 sites, United States
- Primary endpoint
- Maximum Observed Concentration (Cmax) of COC